Note 2 - Significant Accounting Policies (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
|---|
| Notes Tables |
|
| Segment Reporting [Table Text Block] |
| | For the Three Months Ended June 30, | | | For the Six Months Ended June 30, | |
| | 2026 | | | 2025 | | | 2026 | | | 2025 | |
Cost of sales | | $ | 12,475 | | | $ | 12,301 | | | | 22,899 | | | $ | 22,857 | |
General and administrative | | | 5,087 | | | | 6,538 | | | | 11,488 | | | | 12,718 | |
Commercialization | | | 11,280 | | | | 10,517 | | | | 22,163 | | | | 20,707 | |
Research and development: | | | | | | | | | | | | | | | | |
Clinical research and development | | | 10,664 | | | | 7,679 | | | | 22,108 | | | | 14,093 | |
Medical affairs | | | 1,141 | | | | 1,631 | | | | 2,480 | | | | 2,784 | |
Other research and development (1) | | | 6,317 | | | | 5,506 | | | | 12,572 | | | | 11,012 | |
Operating costs and expenses | | | 46,964 | | | | 44,172 | | | | 93,710 | | | | 84,170 | |
Stock-based compensation | | | 1,953 | | | | 1,628 | | | | 3,849 | | | | 3,654 | |
Total operating costs and expenses | | $ | 48,917 | | | $ | 45,800 | | | $ | 97,559 | | | $ | 87,823 | |
|
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] |
| | For the Three Months Ended | | | For the Six Months Ended | |
| | June 30, | | | June 30, | |
| | 2026 | | | 2025 | | | 2026 | | | 2025 | |
Options outstanding | | | 1,886,584 | | | | 3,865,148 | | | | 1,817,407 | | | | 3,993,693 | |
Warrant outstanding | | | 2,116,250 | | | | 2,116,250 | | | | 2,116,250 | | | | 2,116,250 | |
Unvested restricted stock units | | | 0 | | | | 525,067 | | | | 18,816 | | | | 519,545 | |
Totals | | | 4,002,834 | | | | 6,506,465 | | | | 3,952,473 | | | | 6,629,488 | |
|
| Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
| | For the Three Months Ended June 30, | | | For the Six Months Ended June 30, | |
| | 2026 | | | 2025 | | | 2026 | | | 2025 | |
Numerator: | | | | | | | | | | | | | | | | |
Net income | | $ | 8,189 | | | $ | 5,855 | | | $ | 4,436 | | | $ | 8,829 | |
Denominator: | | | | | | | | | | | | | | | | |
Weighted average common stock outstanding for basic net income per share | | | 50,939,946 | | | | 49,700,217 | | | | 50,892,800 | | | | 49,648,246 | |
Net effect of dilutive common stock equivalents | | | 1,656,643 | | | | 444,487 | | | | 1,386,125 | | | | 355,463 | |
Weighted average common stock outstanding for diluted net income per share | | | 52,596,589 | | | | 50,144,704 | | | | 52,278,925 | | | | 50,003,709 | |
Net income per share of common stock | | | | | | | | | | | | | | | | |
Basic | | $ | 0.16 | | | $ | 0.12 | | | $ | 0.09 | | | $ | 0.18 | |
Diluted | | $ | 0.16 | | | $ | 0.12 | | | $ | 0.08 | | | $ | 0.18 | |
|
| Fair Value, Assets Measured on Recurring Basis [Table Text Block] |
June 30, 2026 | | Level 1 | | | Level 2 | | | Level 3 | | | Total | |
Cash Equivalents | | $ | 10,994 | | | $ | 18,393 | | | $ | — | | | $ | 29,387 | |
U.S. Government Securities | | | 21,814 | | | | 12,183 | | | | — | | | | 33,997 | |
Corporate Bonds | | | — | | | | 6,408 | | | | — | | | | 6,408 | |
Commercial Paper | | | — | | | | 16,961 | | | | — | | | | 16,961 | |
| | $ | 32,808 | | | $ | 53,945 | | | $ | — | | | $ | 86,753 | |
December 31, 2025 | | Level 1 | | | Level 2 | | | Level 3 | | | Total | |
Cash Equivalents | | $ | 5,060 | | | $ | 18,710 | | | $ | — | | | $ | 23,770 | |
U.S. Government Securities | | | 27,903 | | | | 14,873 | | | | — | | | | 42,776 | |
Corporate Bonds | | | — | | | | 6,865 | | | | — | | | | 6,865 | |
Commercial Paper | | | — | | | | 18,252 | | | | — | | | | 18,252 | |
Totals | | $ | 32,963 | | | $ | 58,700 | | | $ | — | | | $ | 91,663 | |
|
| Cash, Cash Equivalent, and Investment [Table Text Block] |
| Maturity | | Amortized | | | Unrealized | | | Estimated | |
June 30, 2026 | (in years) | | Cost | | | Gains | | | Losses | | | Fair Value | |
Cash Equivalents | | $ | 29,387 | | | $ | — | | | $ | — | | | $ | 29,387 | |
U.S. Government Securities | Less than 1 | | | 34,030 | | | | — | | | | (33 | ) | | | 33,997 | |
Corporate Bonds | Less than 1 | | | 6,411 | | | | — | | | | (3 | ) | | | 6,408 | |
Commercial Paper | Less than 1 | | | 16,970 | | | | — | | | | (9 | ) | | | 16,961 | |
Totals | | $ | 86,798 | | | $ | — | | | $ | (45 | ) | | $ | 86,753 | |
| Maturity | | Amortized | | | Unrealized | | | Estimated | |
December 31, 2025 | (in years) | | Cost | | | Gains | | | Losses | | | Fair Value | |
Cash Equivalents | | $ | 23,772 | | | $ | — | | | $ | (2 | ) | | $ | 23,770 | |
U.S. Government Securities | Less than 1 | | | 42,739 | | | | 37 | | | | — | | | | 42,776 | |
Corporate Bonds | Less than 1 | | | 6,866 | | | | 1 | | | | (2 | ) | | | 6,865 | |
Commercial Paper | Less than 1 | | | 18,250 | | | | 3 | | | | (1 | ) | | | 18,252 | |
Totals | | $ | 91,627 | | | $ | 41 | | | $ | (5 | ) | | $ | 91,663 | |
|
| Schedule of Inventory, Current [Table Text Block] |
| | June 30, 2026 | | | December 31, 2025 | |
Raw materials | | $ | 10,476 | | | $ | 3,212 | |
Work-in-process | | | 1,794 | | | | 1,343 | |
Finished goods | | | 1,054 | | | | 960 | |
Total inventories | | $ | 13,324 | | | $ | 5,515 | |
|